Subject Category: Cancer
Normally, mammalian cells deploy numerous checkpoint enzymes that ensure faithful cell cycle progression and mitosis. However, if one or more of these checkpoint enzymes are dysregulated, it can result in uncontrolled cell growth and division, eventually leading to neoplastic growth. One of these dysregulated checkpoint proteins is Aurora B; in cancerous cells, Aurora B is highly overexpressed, causing abnormal distribution of DNA, which is highly linked to maligancy. 1, 2 Aurora B kinase is a multi-role protein that localizes within different intracellular organelles, targeting many substrates to regulate different mitotic events. Aurora B has been shown to localize on mitotic chromosomes, specifically associating with kinetochores in metaphase, but dislocates at anaphase and later accumulates on the midzone and midbody. [3] [4] [5] Aurora B has been shown to have important roles in chromosome biorientation, 6 chromosome condensation and cohesion, 7 cytokinesis 8 and the spindle assembly checkpoint. 9 Mammalian cells are extremely sensitive to Aurora B modulation, as chemical inhibition, siRNA knockdown of Aurora B or overexpression of the kinase-dead form of Aurora B, all lead to similar phenotypes, including chromosome misalignment and cytokinesis failure. [10] [11] [12] [13] Aurora B protein is subject to extensive posttranslational modification throughout the cell cycle. For example, the anaphase-promoting complex through binding to the degradation-targeting proteins Cdh1 and Cdc20, or assembly of an E3 ligase complex comprising Cullin3 with the Bric-a-brac-Tramtrack-Broad complex Kelch proteins (KLHL21) is sufficient to ubiquitinate Aurora B. 3, 13, 14 Hence, posttranslational events within Aurora B protein might be important in governing kinase relocation or levels during early phases of the mitotic program, and yet other effectors might regulate local concentrations of Aurora B within the midbody during telophase as feedback inhibitory or activating signals.
The Skp-Cullin-F box (SCF) ubiquitin E3 ligase machinery regulates cell cycle progression, centrosome stability and mitotic fidelity. [15] [16] [17] [18] [19] The SCF complex contains a catalytic core consisting of Skp1, Cullin1 and the E2 ubiquitinconjugating (Ubc) enzyme, and a F-box component that acts as a receptor, targeting numerous substrates via phosphodegron-elicited interactions. [20] [21] [22] [23] There have been limited studies on SCF complex functions during mitosis; however, recently it was demonstrated that the SCF cyclinF complex controls centrosome homeostasis and mitotic fidelity through CP110 degradation. 19 These SCF-based studies focused on centrosome regulation, and thus far their limited data, demonstrating the ability of an F-box protein to target midbody proteins. However, the observation that Skp1 interacts with centromere-associated protein E at the midbody suggests that SCF-based ligase complexes might regulate cytokinesis-associated proteins. 24 Recently, we demonstrated that the SCF subunit, F-box/LRR-repeat protein 2 (FBXL2), targets Aurora B for its ubiquitination to mediate its disposal in cells, an effect antagonized by the calcium sensor, calmodulin. 25 However, given the importance of Aurora B in cell cycle progression, understanding the molecular mechanism whereby FBXL2 targets Aurora B provides an opportunity for devising strategies directed at generating potent SCF FBXL2 agonists that might impact neoplastic growth.
Here our data suggest that FBXL2 acts as a functional inhibitor with regard to cell cycle progression, specifically within mitosis. FBXL2 localizes at the midbody during cytokinesis and exhibits tumor-suppresser activity by site-specific ubiquitination and degradation of Aurora B in human lung cancer cell lines and leukemic cells. Further, we developed a small molecule, BC-1258, which is sufficient to stabilize and upregulate FBXL2 levels, and, when administered in vivo, prematurely depletes Aurora B by SCF FBXL2 -induced ubiquitination and degradation, leading to cell death, and inhibiting growth of human leukemic cells in a xenograft model. This study provides a new strategy for degrading Aurora B protein as a potential means to modulate tumorogenesis.
Results
FBXL2 selectively induces Aurora B degradation. We first tested over 30 F-box proteins that might be involved in Aurora B degradation. Twenty-seven randomly selected F-box plasmids (FBXL, FBXW and FBXO family members) were expressed in a transformed murine lung epithelial (MLE) cell line (Figures 1a-c) . Twenty-four hours later, cells were collected and cell lysates were analyzed for the expression of immunoreactive F-box protein and Aurora B protein. Only the FBXL2 plasmid expression decreased Aurora B protein mass. Next, cells were transfected with increasing amounts of FBXL2 plasmid (Figure 1d ). Aurora B was degraded in a dose-dependent manner. Ectopic FBXL2 plasmid expression significantly decreased the half-life (t 1/2 ) of Aurora B, whereas FBXL2 knockdown markedly increased Aurora B's lifespan (Figure 1e ). We further tested FBXL2 in other cell lines; ectopic expression of FBXL2 plasmid also resulted in a reduction in endogenous Aurora B levels in adenocarcinomic human alveolar basal epithelial cell (A549), human embryonic kidney 293 and B-lymphocyte cell lines (Supplementary Figure S1A) . To assess the specificity of FBXL2 substrate targeting, we tested another related kinase family member, Aurora A, as we previously identified that Aurora A is a substrate of FBXL7. 26 Expression of FBXL2 plasmid did not decrease Aurora A protein levels or its t 1/2 (Supplementary Figures S1B and C) . Moreover, a random F-box plasmid (FBXL16) from the FBXL family was also selected and ectopically expressed in cells demonstrating the lack of ability of this protein to disrupt Aurora B stability (Supplementary Figure S1D) . Consistent with a posttranslational effect, FBXL2 plasmid overexpression did not significantly alter Aurora B steady-state mRNA levels (data not shown).
FBXL2 depletes Aurora B within the midbody during mitosis. Costaining of synchronized MLE cells with FBXL2 and Aurora B antibodies demonstrated that FBXL2 decorated cells in a punctate pattern, but with very specific midzone and midbody localization throughout telophase (Figure 2a) . In general, FBXL2 colocalized with Aurora B throughout cytokinesis. Further, FBXL2 expression in cells enhanced levels of the F-box on the midbody, but drastically changed the morphology of the midbody and depleted cytosolic Aurora B within this organelle (Figure 2b) . As a complementary approach, FBXL2 knockdown decreased F-box expression coupled with a robust increase in Aurora B protein concentrations on the midbody (Figure 2c ). Using MLE cells co-expressing mCherry-tagged histone H2B and MyrPalm-mEGFP as markers for the chromosome and plasma membrane, respectively, we observed that ectopically expressed FBXL2 plasmid induced binucleate cell formation. Specifically, upon FBXL2 plasmid expression, although the furrow ingression was indeed initiated at the end of telophase, it subsequently regressed and resulted in abscission failure and multi-nucleated cells (Figure 2d ). Quantitative analysis revealed that 30% of cells contained two or more nuclei 24 h after FBXL2 plasmid expression (Figure 2e , right).
FBXL2 depletes Aurora B, causes G2/M arrest and inhibits tumorigenesis. Microscopy results were confirmed by flow cytometry, where cells were first transfected with different amounts of FBXL2 plasmid, labeled with bromodeoxyuridine (5-bromo-2 0 -deoxyuridine (BrdU) and then collected for processing by a two-color fluorescenceactivated cell sorting (FACS) after 48 h (Figure 3a) . The results indicate a significant increase in a cell population within the G2/M phase (Figure 4a ). Ectopic expression of FBXL2 tended to reduce the diploid cell population and increase the numbers of polyploid cells in a dose-dependent manner (Figure 3b) . Moreover, ectopic expression of FBXL2 triggered an increase in apoptosis in human lung adenocarcinoma (A549) cells by FACS analysis using Annexin V staining (Figure 3c ). The ability of FBXL2 to induce mitotic abnormalities (Figure 3b ) suggests that it displays tumor suppressor activity. Hence, we first assessed tumorogenicity after implanting A549 cells under stable expression of FBXL2 in athymic nude mice. Stable expression of FBXL2 significantly reduced the tumor size compared with that of the control implants (Figure 3d , upper right panel). Importantly, when tumor tissues were collected from control implants and FBXL2 mice at the end-point and analyzed, immunoblotting showed significant decreases in Aurora B protein levels, coupled with increased levels of FBXL2 protein (Figure 3e , lower panel, n ¼ 4/group).
SCF-FBXL2 targets Aurora B for polyubiquitination. To confirm the specificity of FBXL2 targeting, we performed coimmunoprecipitation (co-IP) experiments. A549 cells were lysed and subjected to IP using Aurora B antibodies and samples used for F-box protein immunoblotting; out of seven E3 ligase subunits tested, FBXL2 was the only protein detected in the Aurora B immunoprecipitates (Figure 4a) . Importantly, inclusion of purified SCF FBXL2 with the full complement of E1 and E2 enzymes, plus ubiquitin, was sufficient to generate polyubiquitinated Aurora B species in vitro (Figure 4b ). To determine the ubiquitination acceptor site within Aurora B, we employed both candidate and deletion mapping approaches; Aurora B deletion mutants were first constructed and synthesized in vitro before testing in a ubiquitination assay ( Figure 4c ). Compared with wild-type (WT) Aurora B and other deletion mutants, a C150 deletion variant and, to a lesser degree, a C200 mutant exhibited resistance to SCF FBXL2 -directed polyubiquitination, suggestive of a potential ubiquitination site or FBXL2-docking motif within the kinase C terminus (Figure 4d ). Point mutagenesis of candidate lysine residues within the NH 2 variant of Aurora B exhibited a significantly extended t 1/2 compared with that of the WT Aurora B (Figure 4f ).
Expression of an Aurora B stable mutant induces apoptosis. Next, to evaluate the biological significance of Aurora B mutants, we transfected the plasmids in cells and assessed cytokinesis. Using MLE cells co-expressing mCherry-tagged histone H2B and MyrPalm-mEGFP as markers, we observed that the expression of Aurora B triple mutant exhibited significantly delayed anaphase onset (Figures 5b and c) . We also observed that the majority of cells (B80%) transfected with the stable Aurora B triple mutant with these chromosomal segregation errors underwent apoptosis versus WT cells (Figures 5c and d) . As Aurora B is known to localize to the kinetochore, these observations suggest persistent expression of a ubiquitination-resistant Aurora B variant within this organelle during metaphase in cells results in disruption of chromosome separation, thus delayed anaphase and furrow ingression, and subsequent induced apoptosis.
BC-1258 induces apoptosis in neoplastic cells by causing mitosis arrest and tetraploidy. FBXL2 is a unique E3 ligase subunit in that it recognizes a calmodulin-binding signature in targets rather than a phosphodegron typical of other F-box proteins. Following its initial description, 23 FBXL2 was shown to be involved in the ubiquitination of the lipogenic enzyme, cytidylyltransferase (CCT). 27, 28 Our recent studies show that FBXL2 targets important cell cycle proteins, cyclin D3 and cyclin D2, for polyubiquitination and degradation. 29 We have also shown that FBXL2 regulates the fidelity of cellular division through centrosomal assembly proteins cyclin-dependent kinase 11 (Cdk11), Aurora A and polo-like kinase 4 (Plk4). 30 Further, FBXL2 is strongly repressed in human lung adenocarcinoma. 31 Recently, we discovered that FBXL2 itself is subject to polyubiquitination and degradation by another SCF F-box protein, F-box-only protein 3 (FBXO3). 32 This led us to design, synthesize and test FBXO3 small molecule inhibitors that might indirectly preserve FBXL2 activity. 32 Upon examining leukemic peripheral blood mononuclear cell samples, we discovered that FBXL2 protein levels are significantly reduced compared with that of the control, while the substrate of FBXL2, Aurora B, is highly overexpressed in (Figure 6a ). To test the hypothesis that Aurora B degradation is sufficient to induce apoptosis and tumor growth, we screened several potential small molecules based on interaction with FBXO3 that might augment FBXL2 activity. One FBXO3 chemical inhibitor, BC-1258, induced FBXL2 concentrations in a variety of cells (unpublished data, Figure 6b ). Although BC-1258 increased FBXL2 protein levels, it decreased FBXL2 substrates, including Aurora B in human leukemia cells (U937 (human leukemic monocyte lymphoma cell line), K562 (human erythroleukemic cell line) and THP1 (human acute monocytic leukemia cell line)) (Figures 6c-e) . We also tested BC-1258 using flow cytometry, where cells were treated with BC-1258 at different concentrations, labeled with BrdU and then collected for processing bya two-color FACS after 48 h (Figure 6f) . The results indicate a significant increase in a cell population within the G2/M phase (Figure 6f ). BC-1258 treatment tended to reduce the diploid cell population and increase the numbers of polyploidal cells in a dose-dependent manner (Figure 6g) . Moreover, BC-1258 triggered a significant increase in apoptosis in MLE cells by FACS analysis using Annexin V staining (Figure 6h ).
BC-1258 inhibits tumorigenesis. As a complementary in vivo model, we further assessed tumorogenicity after implanting U937 cells in athymic nude mice. Here, in various subsets of mice, animals were treated with three benzathinederived small molecules (BC-1250, BC-1206 and BC-1258) that exhibited variable abilities to induce FBXL2 (unpublished observations). Interestingly, we observed significantly reduced tumor size and weight with BC-1258 treatment compared with that of the vehicle or BC-1250-treated implants (Figures 7a-d) . BC-1206 exhibited intermediate ability to suppress tumor growth. Importantly, when tumor tissues were collected from control and treated mice at the endpoint and analyzed, immunoblotting showed significant decreases in Aurora B protein levels with BC-1258 treatment (Figure 7e) . To evaluate the toxicity of tested drugs, serum of each mouse was also taken at the end point, and was assayed for creatinine, lactate dehydrogenase, alanine aminotransferase and creatine kinase activity. Here, BC-1258 did not show significant effects in these physiological markers compared with the vehicle (Figures 7f-i) .
Discussion
Chromosome segregation abnormalities occur frequently in dividing cells, especially during malignant transformation. 33, 34 Usually, defective or delayed chromosome segregation evidenced by lagging or bridged chromosomes will trigger spontaneous furrow regression, resulting in tetraploidization in cells. 35 Hence, a fundamental issue to be addressed during mitosis is the mechanism(s) in which the majority of cells with chromosome bridges are eventually able to suppress furrow regression and complete faithful mitosis. Aurora B is the key regulator of abscission timing, which responds to chromosome bridge formation by delaying abscission to stabilize the intercellular canal until the chromosome bridge is resolved. 36 In essence, Aurora B provides a signal for resolution of trapped chromatin to prevent tetraploidy. 37 Further, cellular concentrations of Aurora B are regulated, in part, by the SCF FBXL2 machinery. 25 On the basis of these observations, one fundamental question pursued in this study is by understanding how Aurora B is ubiquitinated at the midbody by FBXL2, can we design, synthesize and test a small molecule that modulates cell growth. Indeed, herein we identified an FBXL2 inducer that was highly effective in Figure S2) . These observations implicate a role for the F-box protein as a homeostatic sensor that regulates the cytokinesis program through modulation of Aurora B concentrations. This molecular model could be mechanistically significant in providing insight into interventional strategies for carcinogenesis.
When analyzing FBXL2 subcellular localization throughout the cell cycle, FBXL2 specifically localizes within the centrosome during the early phases of mitosis. 30 After anaphase, FBXL2 relocates at the midzone and midbody during the late phase of mitosis (Figure 2a) . In a previous report, Ryser et al. 38 suggested that the RING finger E3 ligase BRCA1-associated RING domain 1 (BARD1) colocalizes with Aurora B on the midbody, though depletion of WT BARD1 had only minor effects on cell growth. Here, ectopic expression FBXL2 drastically changes the morphology of the midbody and depletes Aurora B protein levels within this organelle, resulting in mitotic arrest, tetraploidization and apoptosis (Figures 2 and 3) . Thus, the SCF FBXL2 complex targeting Aurora B during mitosis might be an integral, constitutive mechanism to tightly balance Aurora B concentrations that regulates replicative capacity under native conditions or during repair after cellular injury. Although ubiquitin E3 ligase networks target Aurora B, the ubiquitination acceptor sites have not been identified within the kinase. Further, the precise role of the majority of SCF-based E3 ligases in neoplasia have not been established, although repression of FBXL2 in human lung adenocarcinoma 31 raises the possibility that it might regulate molecular programs involved in mitosis and cell division. In this regard, we showed that FBXL2 is a tumor suppressor, which targets cyclin D3 for polyubiquitination and degradation, and it regulates the fidelity of cellular division through centrosomal assembly proteins Cdk11, Aurora A and Plk4. 29, 30 Indeed, K 207 of Aurora B is essential for its SUMOlyation, 11 chromosomes and promote anaphase. 3, 4, 14 Our findings that overexpressing a ubiquitination-resistant triple Aurora B mutant results in a delay of anaphase onset and mitotic arrest recapitulates the phenotype from KLHL9 E3 ligase depletion. 3, 14 Because of the important role of Aurora B in cytokinesis, and the fact that this kinase is overexpressed in many types of cancer with high proliferative rates and poor prognosis, 39 the identification of novel molecular targets for developing small molecule Aurora B inhibitors remains an attractive strategy. 10, [40] [41] [42] Inhibition of Aurora B kinase causes polyploid cells; however, as these cells have severe chromosomal abnormalities, they eventually stop dividing or undergo apoptosis. One Aurora B inhibitor BI 811283 is currently undergoing phase 2 trials in subjects with advanced solid tumors and acute myeloid leukemia. One advantage of using Aurora B inhibitors as chemotherapeutic agents is their selectivity towards dividing cells. In doing so, this reduces the risk of adverse effects compared with traditional chemotherapeutic modalities. However, it may be more physiologically appealing to identify a small chemical inhibitor that is able to potently reduce Aurora B protein levels rather than just inhibiting its activity to produce a sustained effect. The compound BC-1258 stabilizes FBXL2 to significantly increase its cellular concentrations, which in turn decreases Aurora B protein levels and other FBXL2 substrates, such as cyclin D3, cyclin D2 and CCT. Cyclin D3, cyclin D2 and CCT are highly expressed in cancer tissues and are essential for cell cycle progression. 29, 30, 43 Of note, we have recently demonstrated that BC-1258 and related small molecule FBXL2 inducers act by inhibiting the function of another F-box protein, termed FBXO3.
32 FBXO3 targets a phosphodegron (Thr 404 ) within FBXL2, which is critical for its ability to mediate FBXL2 polyubiquitination and degradation. 32 Thus, BC-1258 appears to act indirectly by opposing the activity of a FBXL2 repressor. Consistent with this indirect mechanism, by optimizing drug concentrations of BC-1258, we were able to induce apoptosis of tumor cells without producing significant weight loss, systemic toxicity or triggering behavioral abnormalities in mice (Figures 7f-i) . Hence, this small chemical entity (BC-1258) may offer a broad range of antitumor activity indirectly targeting many FBXL2 substrates implicated in tumorogenesis; additional studies in larger tumorogenic models and assessment of off-target effects are needed to fully ascertain its therapeutic potential. (e) Tumors from three controls and three drug-treated U937 implants in mice were collected at the end point, and were assayed for Aurora B, cyclin D2 and FBXL2 proteins by immunoblotting. (f-i) Serum of each mouse were collected at the end point and processed for creatinine, lactate dehydrogenase (LDH), alanine aminotransferase (ALT) and creatine kinase activity Materials and Methods Materials. The sources of the transformed MLE cell line and antibodies were described previously. 44, 45 Purified SCF FBXL2 was purchased from Abnova (Walnut, CA, USA). Purified ubiquitin, E1, E2 and cycloheximide were purchased from Calbiochem (La Jolla, CA, USA). Aurora B rabbit polyclonal antibody, g-tubulin and a-tubulin antibodies were purchased from Cell Signaling (Danvers, MA, USA) and Abcam (Cambridge, MA, USA). Cobalt affinity beads were purchased from Clontech (Mountain view, CA, USA). Lipofectamine 2000, mouse monoclonal V5 antibody, fluorescent labeled antibodies, the pcDNA3.1D cloning kit, E. coli One Shot competent cells, the pENTR Directional TOPO cloning kits and the Gateway mammalian expression system were from Invitrogen (Carlsbad, CA, USA). FACS kits were purchased from BD Biosciences (San Jose, CA, USA). The F-box proteins cDNA were purchased from OpenBiosystems (Huntsville, AL, USA). Nucleofector transfection kits were from Amaxa (Gaithersbury, MD, USA). Immobilized protein A/G beads were from Pierce (Rockford, IL, USA). Annexin V staining kits and the complete proteasome inhibitors were from Roche (Madison, WI, USA). Goat polyclonal FBXL2 antibody, scrambled RNA and siRNAs were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit polyclonal FBXL2 antibody was from AvivaBioscience (San Diego, CA, USA). All DNA sequencing was performed by the University of Pittsburgh DNA Core Facility.
Cell culture. MLE cells were cultured in Dulbecco's modified Eagle medium-F12 (Gibco, Grand Island, NY, USA) supplemented with 2-10% fetal bovine serum. A549 cells were cultured in F12/K medium (Gibco) supplemented with 10% fetal bovine serum. THP1, MOLM (egakaryoblastic leukemia cell line), K562 and U937 cells were cultured in RPMI1640 with 10% fetal bovine serum. For half-life studies, cells were treated with cycloheximide (40 mg/ml) at different time points in blank medium. Cells lysates were prepared by brief sonication in 150 mM NaCl, 50 mM Tris, 1.0 mM EDTA, 2 mM dithiothreitol, 0.025% sodium azide and 1 mM phenylmethylsulfonyl fluoride (Buffer A) at 4 1C.
Expression of recombinant protein and RNAi. All plasmids were delivered into cells using nucleofection or Lipofectamine 2000. 46 ,47 Cellular expression of green fluorescent-tagged plasmids using this device was achieved at 490%. For siRNA studies, 1 Â 10 6 cells were transfected using Lipofectamine 2000 with 10 mg of RNA and were collected after an additional 48 h.
Co-IP and binding assays. Two hundred and fifty micrograms of total protein from cell lysates was precleared with 20 ml of protein A/G beads for 1 h at 4 1C. Five micrograms of primary antibody was added for 18 h of incubation at 4 1C. Foty microliters of protein A/G beads were added for an additional 6 h of incubation. Beads were slowly centrifuged and washed five times using 50 mM HEPES, 150 mM NaCl, 0.5 mM EGTA, 50 mM NaF, 10 mM Na 3 VO 4 , 1mM phenylmethylsulfonyl fluoride, 20 mM leupeptin and 1% (v/v) Triton X-100 (RIPA) buffer, as described. 48 The beads were heated at 100 1C for 5 min with 80 ml of protein sample buffer before SDS-PAGE and immunoblotting.
Microscopy and immunostaining. All the microscopy work was done on a Nikon (Nikon Instruments, Melville, NY, USA) A1 confocal microscope using a Â 60 oil objective. The microscope was equipped with Ti Perfect Focus system and Tokai Hit live cell chamber (Nikon Instruments) providing a humidified atmosphere at 37 1C with 5% CO2. For long-term movie acquisition, sample illumination was kept to minimum to reduce the effect of photobleaching. Transfected cells (2 Â 10 5 ) were plated at 70% confluence on 35 mm MatTek glass bottom culture dishes. Immunofluorescent cell imaging was performed on a Nikon A1 confocal microscope using 405, 458, 488, 514 or 647 nm wavelengths. All experiments were done with a 60 Â oil differential interference contrast objective lens. Cells were washed with PBS and fixed with 4% paraformaldehyde for 20 min, then exposed to 2% BSA, 1 : 500 primary antibodies, and 1 : 1000 Alexa 488-, Alexa 567-or Alexa 647-labeled chicken anti-mouse, donkey anti-goat or goat anti-rabbit secondary antibody sequentially for immunostaining. Image analysis was by Nikon NIS-element (Nikon Instruments) and ImageJ software (National Institutes of Health, Bethesda, MD, USA).
In vitro ubiquitin conjugation assays. The ubiquitination of V5-Aurora B was performed in a volume of 25 ml containing 50 mM Tris pH 7.6, 5 mM MgCl 2 , 0.6 mM DTT, 2 mM ATP, 1.5 ng/ml E1, 10 ng/ml Ubc5, 10 ng/ml Ubc7, 1 mg/ml ubiquitin (Calbiochem), 1 mM ubiquitin aldehyde, 4-16 ml of purified Cullin1, Skp1, Rbx1 and in vitro synthesized FBXL2. Reaction products were processed for V5 immunoblotting.
Quantitative RT-PCR, cloning and mutagenesis. Total RNA was isolated and reverse transcription was performed followed by quantitative real-time PCR with SYBR Green qPCR mixture as described. 49 PCR-based approaches were used to clone different F-box proteins into pcDNA3.1D/v5-his (Invitrogen) for constitutive expression in cells. All mutant constructs were generated using PCR-based approaches using appropriate primers or site-directed mutagenesis.
Cell cycle and apoptosis analysis. Transfected cells were incubated with BrdU (20 mM) for 40 min, fixed and stained following the manufacturer's protocols (BD Biosciences, Sparks, MD, USA). FACS samples were analyzed with the AccuriC6 system. DNA content was analyzed using FCS3 express software (De Novo Software, Los Angeles, CA, USA). When analyzing the cell cycle, a gate for 7AAD was set to exclude polyploidy cells. Otherwise, cells were counted and the percentage of cells with 2N, 4N and 8N DNA content was expressed as a percentage of total cells. Cells were also stained with Annexin V for 15 min following the manufacturer's protocol (Roche). Apoptotic cells were counted, and apoptotic cells were expressed as a percentage of total cells.
Animal studies. Nude/Nude mice (purchased from Charles River, Wilmington, MA, USA) were acclimated at the University of Pittsburgh Animal Care Facility and were maintained according to all federal guidelines and under the University of Pittsburgh Institutional Animal Care and Use Committee approved protocols. Mice were deeply anesthetized with ketamine (80-100 mg/kg intraperitoneally (i.p.) and xylazine (10 mg/kg i.p.), followed by i.p. injection of 5 Â 10 6 A549 cells (100 ml) into the right shoulder. For BC-1258 treatment, an aliquot of bc-1258 stock solution (5 mg/ml) was added to drinking water (containing 2% sucrose) to maintain the final drug concentration at 30 mg/ml. Mice were closely monitored every week; tumor volume was calculated using a formula length Â width Â height Â p/6. Statistical analysis. Statistical comparisons were performed with the Prism program, version 4.03 (GraphPad Software, Inc., San Diego, CA, USA) using an ANOVA 1 or an unpaired 2 Student's t-test with Po0.05 indicative of significance.
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